Pharmaceutical

Verastem files patent for combination treatment of FAK inhibitor and immunotherapy for cancer

Discover how Verastem Inc.'s patent combines FAK inhibitors with immunotherapeutic agents like anti-PD-1 to enhance cancer treatment efficacy in humans. Explore the innovative method targeting immune checkpoint blockade pathways.

Mar 24, 2024 - 00:00
Discover how Verastem Inc.'s patent combines FAK inhibitors with immunotherapeutic agents like anti-PD-1 to enhance cancer treatment efficacy in humans. Explore the innovative method targeting immune checkpoint blockade pathways.
Read the original article

Tags:

Previous Article

Chinook Therapeutics files patent for improving kidney function in a subject

Next Article

Ascendis Pharma files patent for ocular drug delivery system using cross-linked Ha

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Meitheal gains rights to CONTEPO from Nabriva in North America

Meitheal gains rights to CONTEPO from Nabriva in North ...

Jul 20, 2024

Injectables manufacturing ushers in a new era of accessibility

Injectables manufacturing ushers in a new era of access...

Nov 5, 2024

STAT+: Pharmalittle: Novartis is losing its chief commercial officer; vaccine experts urge more inclusivity in clinical trials

STAT+: Pharmalittle: Novartis is losing its chief comme...

Sep 6, 2023